Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 19-64 years old~* Informed consent form has been signed and dated~* Able to comply with the requirements of the study~Exclusion Criteria:~* Known systemic hypersensitive to eggs, chicken proteins, or any of the vaccine components~* Personal history of Guillain-Barre syndrome(GBS)~* Subjects with severe chronic disease who are considered by investigator to be ineligible for the study~* Subjects who received a vaccination within 28 days before enrollment or who are scheduled for another vaccination during the study~* Immunocompromised subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- GC3114 (Type: EXPERIMENTAL): Pre-filled syringe inj., 0.5ml, Once, IM
- GCFLU Quadrivalent (Type: ACTIVE_COMPARATOR): Pre-filled syringe inj., 0.5ml, Once, IM

Based on this trial design, predict the completion outcome and termination type (if applicable).